Silence Therapeutics Plc American Depository Share SLN
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $53.50 (+293.1% upside)
Key Stats
- Today's Range
- $13.47 – $14.59
- 50-Day Range
- $5.88 – $17.58
- 52-Week Range
- $4.19 – $17.58
- Volume
- 974K shs
- Average Volume
- 1.43 million shs
- Market Cap
- $845.92 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 21.99
- Price / Sales
- 1375.47
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.25
Financials (TTM)
- Revenue
- $615,000
- Net Income
- $-59,953,000
- Net Margin
- -9748.46%
- Return on Equity
- -155.84%
- Debt-to-Equity
- —
About Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Related Stocks
Compare head-to-head: SLN vs LLY·SLN vs JNJ·SLN vs ABBV·SLN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.